Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Biochemical Reagents >  Agonist Inhibitors >  MK-0773

MK-0773

Basic information Safety Supplier Related

MK-0773 Basic information

Product Name:
MK-0773
Synonyms:
  • MK-0773
  • PF 05314882
  • PF05314882
  • PF-05314882
  • N-(3H-Imidazo[4,5-b]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
  • MK0773;MK 0773;PF 05314882;PF-05314882;PF05314882
  • 1H-Indeno[5,4-f]quinoline-7-carboxamide, 3-fluoro-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-1,4a,6a-trimethyl-2-oxo-, (4aS,4bS,6aS,7S,9aS,9bS,11aR)-
  • MK 0773,MK0773
CAS:
606101-58-0
MF:
C27H34FN5O2
MW:
479.59
Mol File:
606101-58-0.mol
More
Less

MK-0773 Chemical Properties

Boiling point:
754.2±60.0 °C(Predicted)
Density 
1.31±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO : 33.33 mg/mL (69.50 mM; Need ultrasonic)
form 
Powder
pka
10.29±0.40(Predicted)
color 
Light yellow to yellow
More
Less

MK-0773 Usage And Synthesis

Uses

MK-0773 is a selective androgen receptor modulator designed to improve muscle function while minimizing effects on other tissues. Furthermore, MK-0773 is useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal

in vivo

MK-0773 (6 and 80 mg/kg, s.c.) produces exposure-related stimulatory effects on cortical BFR and LBM in the OVX rat model. MK-0773 (5, 15, and 80 mg/kg, s.c.) increases seminal vesicle weights, and has reduced effects on the prostate. The partial agonism and tissue selectivity of MK-0773 does not translate into differential effects on lipid metabolism in OVX rats[1].

target

androgen receptor

MK-0773Supplier

Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070 13913916777;
Email
info@chemlin.com.cn
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
SPIRO PHARMA
Tel
Email
eric_feng1954@126.com
PURE SYNMR INGREDIENTS LIMITED
Tel
021-26015538
Email
sven_shi@puresynmr.com
Codow Chemical Co.,Ltd.
Tel
18620099427
Email
amy@howeipharm.com